Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

IPR-803

Copy Product Info
😃Good
Catalog No. T11666Cas No. 892243-35-5

IPR-803 is an effective inhibitor of the uPAR·uPA protein-protein interaction (PPI) with anti-tumor activity. IPR-803 binds directly to uPAR with a Ki of 0.2 μM.

IPR-803

IPR-803

Copy Product Info
😃Good
Purity: 95%
Catalog No. T11666Cas No. 892243-35-5
IPR-803 is an effective inhibitor of the uPAR·uPA protein-protein interaction (PPI) with anti-tumor activity. IPR-803 binds directly to uPAR with a Ki of 0.2 μM.
Pack SizePriceUSA WarehouseGlobal WarehouseQuantity
1 mg$84-In Stock
5 mg$197-In Stock
10 mg$3286-8 weeks6-8 weeks
25 mg$5586-8 weeks6-8 weeks
50 mg$7886-8 weeks6-8 weeks
1 mL x 10 mM (in DMSO)$2266-8 weeks6-8 weeks
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Questions
TargetMol
View More

Batch Information

Select Batch
Purity:95%
Appearance:Solid
Color:Red
Contact us for more batch information

Resource Download

Product Introduction

Bioactivity
Description
IPR-803 is an effective inhibitor of the uPAR·uPA protein-protein interaction (PPI) with anti-tumor activity. IPR-803 binds directly to uPAR with a Ki of 0.2 μM.
Targets&IC50
PPI:ki: 0.2 μM
In vitro
IPR-803 (0-200 μM; 3 days) blocks the invasion of MDA-MB-231 cells, and most of the inhibition of cell invasion is unlikely due to the cytotoxicity of the compound. IPR-803 (50 μM; 30 minutes) shows inhibition of MAPK phosphorylation. IPR-803 blocks invasion of breast cancer cells line MDA-MB-231, and inhibits matrix metalloproteinase breakdown of the extracellular matrix. IPR-803 impairs MDA-MB-231 cell adhesion and migration. IPR-803 induces a concentration-dependent impairment of cell adhesion with an IC50 of 30 μM. IPR-803 inhibits MDA-MB-231 cells growth with an IC50 of 58 μM[1].
In vivo
In NSG mice with MDA-MB-231 cells xenograft, IPR-803 (200 mg/kg; i.g.; three times a week; for 5 weeks) impairs breast cancer metastasis with a t1/2 of 5 hours. IPR-803 has a low oral bioavailability at 4 percent, and remains high concentration even after 10 hours in tumor tissue[1].
Chemical Properties
Molecular Weight453.49
FormulaC27H23N3O4
Cas No.892243-35-5
SmilesOC(=O)c1cccc(Nc2cc(N3CCCCCC3)c3noc4-c5ccccc5C(=O)c2c34)c1
Relative Density.1.401 g/cm3 (Predicted)
Storage & Solubility Information
Storagestore at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
Solubility Information
DMSO: 7 mg/mL (15.44 mM), Sonication is recommended.
Solution Preparation Table
DMSO
1mg5mg10mg50mg
1 mM2.2051 mL11.0256 mL22.0512 mL110.2560 mL
5 mM0.4410 mL2.2051 mL4.4102 mL22.0512 mL
10 mM0.2205 mL1.1026 mL2.2051 mL11.0256 mL

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
TargetMol | Animal experiments For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent 10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.
Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSOTargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSOTargetMol | reagent stock solution to 400 μL PEG300TargetMol | reagent and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH2OTargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
% Tween 80
% Saline/PBS/ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords

Related Tags: buy IPR-803 | purchase IPR-803 | IPR-803 cost | order IPR-803 | IPR-803 chemical structure | IPR-803 in vivo | IPR-803 in vitro | IPR-803 formula | IPR-803 molecular weight